UY32235A - Combinacion farmaceutica sinergica que comprende un antagonista del receptor de estrogeno y una progestina - Google Patents

Combinacion farmaceutica sinergica que comprende un antagonista del receptor de estrogeno y una progestina

Info

Publication number
UY32235A
UY32235A UY0001032235A UY32235A UY32235A UY 32235 A UY32235 A UY 32235A UY 0001032235 A UY0001032235 A UY 0001032235A UY 32235 A UY32235 A UY 32235A UY 32235 A UY32235 A UY 32235A
Authority
UY
Uruguay
Prior art keywords
antigonist
progestine
strogen
pharmaceutical
receiver
Prior art date
Application number
UY0001032235A
Other languages
English (en)
Spanish (es)
Inventor
Dr Tim Wintermantel
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of UY32235A publication Critical patent/UY32235A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
UY0001032235A 2008-11-11 2009-11-10 Combinacion farmaceutica sinergica que comprende un antagonista del receptor de estrogeno y una progestina UY32235A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102008057230A DE102008057230A1 (de) 2008-11-11 2008-11-11 Synergistische pharmazeutische Kombination mit einem Estrogenrezeptorantagonisten und einem Progestin

Publications (1)

Publication Number Publication Date
UY32235A true UY32235A (es) 2010-06-30

Family

ID=41606625

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032235A UY32235A (es) 2008-11-11 2009-11-10 Combinacion farmaceutica sinergica que comprende un antagonista del receptor de estrogeno y una progestina

Country Status (6)

Country Link
AR (1) AR074297A1 (zh)
DE (1) DE102008057230A1 (zh)
PA (1) PA8847901A1 (zh)
TW (1) TW201022251A (zh)
UY (1) UY32235A (zh)
WO (1) WO2010054758A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120238533A1 (en) * 2009-09-11 2012-09-20 Bayer Pharma Aktiengesellschaft (Heteroarylmethyl) Thiohydantoins as anticancer drugs
US20130231292A1 (en) * 2012-03-02 2013-09-05 Wei Zhou Synergistic anti-proliferation activity of TAS-108 with mTOR inhibitors against cancer cells
US10112962B2 (en) * 2014-07-02 2018-10-30 Xavier University Boron-based prodrug strategy for increased bioavailability and lower-dosage requirements for drug molecules containing at least one phenol (or aromatic hydroxyl) group
CN104370796B (zh) * 2014-11-21 2016-09-14 扬子江药业集团有限公司 一种醋酸巴多昔芬多晶型b的制备方法
KR20180059427A (ko) * 2015-07-14 2018-06-04 노벨파마 컴퍼니 리미티드 에스트로겐 수용체 α 저해 작용을 갖는 에스트로겐 수용체 β 부분 아고니스트 및 이를 사용한 부인과 질환 치료제

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19635525A1 (de) 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
ID24568A (id) * 1997-11-06 2000-07-27 American Home Prod Kontrasepsi oral yang mengandung anti-estrogen plus progestin
US6265393B1 (en) 1998-08-07 2001-07-24 Heinrichs William Leroy Prevention of endometriosis signs or symptons
WO2001009115A2 (en) * 1999-07-29 2001-02-08 Eli Lilly And Company A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3- (4-[2-(PIPERIDIN-1- YL)ETHOXY] PHENOXY)-2- (4-METHOXYPHENYL) BENZO[b]THIOPHENE HYDROCHLORIDE
DE10013782A1 (de) 2000-03-15 2001-10-18 Schering Ag 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
DE10159217A1 (de) 2001-11-27 2003-06-05 Schering Ag 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
WO2003063859A1 (en) * 2002-01-14 2003-08-07 Nordic Bioscience A/S Suppression of cartilage degradation via the estrogen receptor
TW200307553A (en) * 2002-05-24 2003-12-16 Akzo Nobel Nv Treatment of post-menopausal complaints in breast cancer patients
NZ537138A (en) 2002-07-22 2007-11-30 Lilly Co Eli Selective estrogen receptor modulators containing a phenylsulfonyl group
US20080021003A1 (en) * 2006-06-13 2008-01-24 Vladimir Hanes Extended step-down estrogen regimen

Also Published As

Publication number Publication date
AR074297A1 (es) 2011-01-05
TW201022251A (en) 2010-06-16
PA8847901A1 (es) 2010-06-28
DE102008057230A1 (de) 2010-05-12
WO2010054758A1 (en) 2010-05-20

Similar Documents

Publication Publication Date Title
CR20110455A (es) Derivados de indol como antagonistas del receptor crth2
UY32819A (es) Composiciones farmaceuticas de uso oftalmico de antagonistas del receptor dp2
GT201500233A (es) Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
GT201200147A (es) Antagonistas de espiro-oxindol de mdm2
CR20150296A (es) Novedosos derivados de bencimidazol como antagonistas de ep4
GT201600056A (es) Derivados de quinolizina sustituidos utiles como inhibidores de integrasa del vih
GT201300122A (es) Antagonistas del receptor del cgrp de piperidinona carboxamida azaindano
NI201500004A (es) Métodos y composiciones para determinar la resistencia a la terapia con receptor de andrógeno.
CO6480918A2 (es) Antagonistas policíclicos de receptores de ácido lisofosfatídico.
UY32926A (es) Compuestos como antagonistas de los receptores de ácido lisofosfatídico
UY30829A1 (es) Compuestos agonistas y antagonistas del receptor de esfinfosina-1-fosfato
CO6680708A2 (es) Compuesto modulares de estrógenos y composiciones que comprenden los mismos
CO6640327A2 (es) Compuestos de pirazol como inhibidores del receptor sigma
SV2010003687A (es) Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
AU2013235499A8 (en) Estrogen receptor modulators and uses thereof
HN2012000137A (es) Derivados de 17 - hidroxi - 17 - pentafluoroetil - estra - 4, 9(10) - dien - 11 - arilo, procedimientos para su preparacion y su uso para el tratamiento de enfermedades
DOP2013000043A (es) Composiciones y métodos para inhibir la unión de células madre y células progenitoras a tejido linfoide y para regenerar centros germinales en tejidos linfáticos
UY32235A (es) Combinacion farmaceutica sinergica que comprende un antagonista del receptor de estrogeno y una progestina
CU20120175A7 (es) Compuestos derivados de 6,7-dihidro-5h-benzo[7]anulenos
CO6420342A2 (es) Derivados de pirazol usados como antagonistas del receptor ccr4
BR112015030387A2 (pt) compostos de pirazol como moduladores de fshr e usos dos mesmos
GT201300241A (es) Composicion farmaceutica antihipertensiva
UY35906A (es) Novedosos derivados de bencimidazol como ligandos de ep4
CL2016002240A1 (es) Derivados de piperidina como antagonista de receptores de orexina

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181127